5 Star
02 June 2018

. .
  • .

    Serena to face Sharapova, Nadal downs Gasquet


    Jun 3, 2018
  • .

    There are no comments.


    Roles Formal analysis, Investigation, Methodology, Writing – review & editing

    Affiliation Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States of America

  • Yuhui Whitney Yin, .
    Our Online Games

    Play right from this page


    Results to be presented during the developmental therapeutics session
    at the ASCO 2018 Annual Meeting

    today announced that its affiliate company, NantOmics,
    , will present results from the NantOmics pharmacogenomics test,
    an integrative panomic approach to pharmacogenomics screening, during
    the developmental therapeutics session at the American
    Society of Clinical Oncology (ASCO) 2018 Annual Meeting
    , an event
    bringing together 30,000 oncology professionals from June 1-5, 2018 at
    McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
    booth #7147 during the event.

    “Our goal was to develop a more effective way to accurately detect
    pharmacogenomic variants in oncology patients,” said Patrick
    Soon-Shiong, MD, founder of NantWorks. “We are excited to share how
    we’re not only fulfilling this industry need with our pharmacogenomics
    test, but also how we’re tailoring therapies to a patient’s specific
    genotype in order to optimize testing.”

    Presentation Details

    NantOmics Pharmacogenomics Test: An integrative panomic approach to
    pharmacogenomics screening
    , Abstract #2575
    NantOmics, LLC and NantKwest, LLC
    WHAT: Developmental
    Therapeutics Session
    WHEN: June 4, 8:00-11:30 AM CST
    Hall A, McCormick Place

    Presentation Summary

    Pharmacogenomics screening was performed on whole genome and whole exome
    sequencing data of FFPE tumors and their matched normal tissues from
    1,879 oncology patients. The test observed how allele frequencies
    correspond well to known population frequencies, and validation studies
    demonstrated that the test detects each variant in a panel, and
    correctly determines patient genotype in all studied cases. Given the
    high percentage of patients with potentially treatment-altering genomic
    variants, these results underscore the need for more routine
    pharmacogenomics screening in the oncological setting.

    About NantOmics

    NantOmics, a member of the NantWorks ecosystem of companies, delivers
    molecular analysis capabilities with the intent of providing actionable
    intelligence and molecularly driven decision support for cancer patients
    and their providers at the point of care. NantOmics is the first
    molecular analysis company to pioneer an integrated approach to
    unearthing the genomic and proteomic variances that initiate and drive
    cancer, by analyzing both normal and tumor cells from the same patient
    and following identified variances through from DNA to RNA to protein to
    drug. NantOmics has a highly scalable cloud-based infrastructure capable
    of storing and processing thousands of genomes a day, computing genomic
    variances in near real-time, and correlating proteomic pathway analysis
    with quantitative multi-plexed protein expression analysis from the same
    micro-dissected tumor sample used for genomic analysis. For more
    information please visit www.nantomics.com and
    follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.


    Jen Hodson
    [email protected]
    Jackson, 310-486-8908
    [email protected]